Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004165 · ClinicalTrials.gov registry record · Phase 3
Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
A Phase 3 study of Multiple Myeloma and Plasma Cell Neoplasm, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 3
- Development phase
- 1
- Study location
NCT00004165: Completed Phase 3 study of Multiple Myeloma and Plasma Cell Neoplasm, sponsored by Northwestern University.
NCT00004165 is a Phase 3 study of Multiple Myeloma and Plasma Cell Neoplasm that has completed, run by Northwestern University. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004165, a Phase 3 study of Multiple Myeloma and Plasma Cell Neoplasm, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1
- Study location
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Phase III trial to study the effectiveness of melphalan followed by peripheral stem cell transplantation in treating patients who have multiple myeloma.
Conditions Studied
Interventions
- DRUG melphalan
- PROCEDURE peripheral blood stem cell transplantation
- BIOLOGICAL filgrastim
Study Locations (1)
Illinois
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-10 |
| Est. Completion | 2003-08 |
| Phase | Phase 3 |
What the finished NCT00004165 record still lists
NCT00004165 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with Multiple Myeloma and Plasma Cell Neoplasm appearing as the primary indexed condition, and to 3 interventions - of which melphalan is the first listed.
NCT00004165 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT00004165 about?
NCT00004165 is a clinical study titled "Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Phase III trial to study the effectivene...
What is the current status of trial NCT00004165?
This trial is currently completed. It is a Phase 3 study. The study started on 1999-10. Estimated completion is 2003-08.
What conditions does trial NCT00004165 study?
This clinical trial studies the following conditions: Multiple Myeloma and Plasma Cell Neoplasm.
What interventions are being tested in trial NCT00004165?
The interventions under investigation include: melphalan (DRUG), peripheral blood stem cell transplantation (PROCEDURE), filgrastim (BIOLOGICAL).
Who is sponsoring clinical trial NCT00004165?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00004165 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma and Plasma Cell Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy
COMPLETED · Phase 3
-
Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma
COMPLETED · Phase 3
-
Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma
COMPLETED · Phase 3
-
Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain
COMPLETED · Phase 3
-
Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter
COMPLETED · Phase 3
-
Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia